Effects of metalloporphyrins on reducing inflammation and autoimmunity

Antioxidants and Redox Signaling

Volumn 20, Issue 15, 2014, Pages 2465-2477

  Delmastro Greenwood, Meghan M ^a,b   Tse, Hubert M ^a,c   Piganelli, Jon D ^a,b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPORPHYRIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL PROTECTION; DRUG EFFECT; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ANIMAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; TRANSPLANTATION;

ANIMALS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSION; INFLAMMATION; INSULIN-SECRETING CELLS; LYMPHOCYTES; METALLOPORPHYRINS; OXIDATIVE STRESS;

EID: 84899743722     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5257     Document Type: Review

References (146)

1. Adler V, Yin Z, Tew KD, and Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene 18: 6104-6111, 1999.
2. Ammendola R, Mesuraca M, Russo T, and Cimino F. The DNA-binding efficiency of Sp1 is affected by redox changes. Eur J Biochem 225: 483-489, 1994.
3. Amrani A, Verdaguer J, Anderson B, Utsugi T, Bou S, and Santamaria P. Perforin-independent beta-cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice. J Clin Invest 103: 1201-1209, 1999.
4. Anglicheau D and Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation 86: 192-199, 2008.
5. Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, and Corbett JA. IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 102: 516-526, 1998.
6. Bach JF, Bendelac A, Brenner MB, Cantor H, De Libero G, Kronenberg M, Lanier LL, Raulet DH, Shlomchik MJ, and von Herrath MG. The role of innate immunity in autoimmunity. J Exp Med 200: 1527-1531, 2004.
7. Barlow AD, Xie J, Moore CE, Campbell SC, Shaw JA, Nicholson ML, and Herbert TP. Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2). Diabetologia 55: 1355-1365, 2012.
8. Batinic-Haberle I, Cuzzocrea S, Reboucas JS, Ferrer-Sueta G, Mazzon E, Di Paola R, Radi R, Spasojevic I, Benov L, and Salvemini D. Pure MnTBAP selectively scavenges peroxynitrite over superoxide: comparison of pure and commercial MnTBAP samples to MnTE-2-PyP in two models of oxidative stress injury, an SOD-specific Escherichia coli model and carrageenan-induced pleurisy. Free Radic Biol Med 46: 192-201, 2009.
9. Batinic-Haberle I, Liochev SI, Spasojevic I, and Fridovich I. A potent superoxide dismutase mimic: manganese betaoctabromo-meso-tetrakis-(N- methylpyridinium-4-yl) porphyrin. Arch Biochem Biophys 343: 225-233, 1997.
10. Batinic-Haberle I, Rajic Z, Tovmasyan A, Reboucas JS, Ye X, Leong KW, Dewhirst MW, Vujaskovic Z, Benov L, and Spasojevic I. Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics. Free Radic Biol Med 51: 1035-1053, 2011.
11. Batinic-Haberle I, Spasojevic I, Tse HM, Tovmasyan A, Rajic Z, St Clair DK, Vujaskovic Z, Dewhirst MW, and Piganelli JD. Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities. Amino Acids 42: 95-113, 2012.
12. Beyan H, Buckley LR, Yousaf N, Londei M, and Leslie RD. A role for innate immunity in type 1 diabetes? Diabetes Metab Res Rev 19: 89-100, 2003.
13. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, and Cerretti DP. A metalloproteinase disintegrin that releases tumournecrosis factor-alpha from cells. Nature 385: 729-733, 1997.
14. Bottino R, Balamurugan AN, Bertera S, Pietropaolo M, Trucco M, and Piganelli JD. Preservation of human islet cell functional mass by anti-oxidative action of a novel SOD mimic compound. Diabetes 51: 2561-2567, 2002.
15. Bottino R, Balamurugan AN, Tse H, Thirunavukkarasu C, Ge X, Profozich J, Milton M, Ziegenfuss A, Trucco M, and Piganelli JD. Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes 53: 2559-2568, 2004.
16. Bour-Jordan H and Bluestone JA. B-cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest 117: 3642-3645, 2007.
17. Butterfield DA and Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid betapeptide-associated free radical oxidative stress. Free Radic Biol Med 32: 1050-1060, 2002.
18. Campbell IL, Oxbrow L, West J, and Harrison LC. Regulation of MHC protein expression in pancreatic beta-cells by interferon-gamma and tumor necrosis factor-alpha. Mol Endocrinol 2: 101-107, 1988.
19. Cantor J and Haskins K. Effector function of diabetogenic CD4 Th1 T cell clones: a central role for TNF-alpha. J Immunol 175: 7738-7745, 2005.
20. Cantu D, Schaack J, and Patel M. Oxidative inactivation of mitochondrial aconitase results in iron and H2O2-mediated neurotoxicity in rat primary mesencephalic cultures. PLoS One 4: e7095, 2009.
21. Chandra J, Samali A, and Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 29: 323-333, 2000.
22. Chen J, Gusdon AM, Thayer TC, and Mathews CE. Role of increased ROS dissipation in prevention of T1D. Ann N Y Acad Sci 1150: 157-166, 2008.
23. Christianson SW, Shultz LD, and Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 42: 44-55, 1993.
24. Chung YH, Jun HS, Kang Y, Hirasawa K, Lee BR, Van Rooijen N, and Yoon JW. Role of macrophages and macrophagederived cytokines in the pathogenesis of Kilham rat virusinduced autoimmune diabetes in diabetes-resistant Biobreeding rats. J Immunol 159: 466-471, 1997.
25. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, and Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54 Suppl 2: S97-S107, 2005.
26. Crapo JD. Oxidative stress as an initiator of cytokine release and cell damage. Eur Respir J Suppl 44: 4s-6s, 2003.
27. Csiszar A, Podlutsky A, Podlutskaya N, Sonntag WE, Merlin SZ, Philipp EE, Doyle K, Davila A, Recchia FA, Ballabh P, Pinto JT, and Ungvari Z. Testing the oxidative stress hypothesis of aging in primate fibroblasts: is there a correlation between species longevity and cellular ROS production? J Gerontol A Biol Sci Med Sci 67: 841-852, 2012.
28. Day BJ, Batinic-Haberle I, and Crapo JD. Metalloporphyrins are potent inhibitors of lipid peroxidation. Free Radic Biol Med 26: 730-736, 1999.
29. Day BJ, Fridovich I, and Crapo JD. Manganic porphyrins possess catalase activity and protect endothelial cells against hydrogen peroxide-mediated injury. Arch Biochem Biophys 347: 256-262, 1997.
30. Deacon K, Onion D, Kumari R, Watson SA, and Knox AJ. Elevated SP-1 transcription factor expression and activity drives basal and hypoxia-induced vascular endothelial growth factor (VEGF) expression in non-small cell lung cancer. J Biol Chem 287: 39967-39981, 2012.
31. Delmastro MM, Styche AJ, Trucco MM, Workman CJ, Vignali DA, and Piganelli JD. Modulation of redox balance leaves murine diabetogenic TH1 T cells "LAG-3-ing" behind. Diabetes 61: 1760-1768, 2012.
32. Delovitch TL and Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7: 727-738, 1997.
33. Duncan MD and Wilkes DS. Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections. Proc Am Thorac Soc 2: 449-455, 2005.
34. El-Gouhary I, Mohamed A, Suleiman S, and Benghuzzi H. Comparison of the amelioration effects of two enzyme inducers on the inflammatory process of experimental allergic encephalitis (EAE) using immunohistochemical technique. Biomed Sci Instrum 41: 376-381, 2005.
35. Eriksson U, Kurrer MO, Sonderegger I, Iezzi G, Tafuri A, Hunziker L, Suzuki S, Bachmaier K, Bingisser RM, Penninger JM, and Kopf M. Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J ExpMed 197: 323-331, 2003.
36. Ferrer-Sueta G, Vitturi D, Batinic-Haberle I, Fridovich I, Goldstein S, Czapski G, and Radi R. Reactions of manganese porphyrins with peroxynitrite and carbonate radical anion. J Biol Chem 278: 27432-27438, 2003.
37. Gallagher MP, Kelly PJ, Jardine M, Perkovic V, Cass A, Craig JC, Eris J, and Webster AC. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 21: 852-858, 2010.
38. Gallichan WS, Balasa B, Davies JD, and Sarvetnick N. Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. J Immunol 163: 1696-1703, 1999.
39. Gee JM and Knowlden JM. ADAM metalloproteases and EGFR signalling. Breast Cancer Res 5: 223-224, 2003.
40. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14: 619-633, 1965.
41. Giacco F and Brownlee M. Oxidative stress and diabetic complications. Circ Res 107: 1058-1070, 2010.
42. Glimcher LH and Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev 14: 1693-1711, 2000.
43. Gould DS and Auchincloss H, Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 20: 77-82, 1999.
44. Grau GE, Lambert PH, Vassalli P, and Piguet PF. Tumor necrosis factor/cachectin as an effector of T cell-dependent immunopathology. Int Rev Exp Pathol 34 Pt B: 159-171, 1993.
45. Healy CM, Rench MA, and Baker CJ. Importance of timing of maternal tdap immunization and protection of young infants. Clin Infect Dis 56: 539-544, 2012.
46. Held W, MacDonald HR, Weissman IL, Hess MW, and Mueller C. Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci U S A 87: 2239-2243, 1990.
47. Huard B, Prigent P, Tournier M, Bruniquel D, and Triebel F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG- 3)-Ig fusion proteins. Eur J Immunol 25: 2718-2721, 1995.
48. Hultcrantz M, Jacobson S, Hill NJ, Santamaria P, and Flodstrom-Tullberg M. The target cell response to cytokines governs the autoreactive T cell repertoire in the pancreas of NOD mice. Diabetologia 52: 299-305, 2009.
49. Hung JT, Liao JH, Lin YC, Chang HY, Wu SF, Chang TH, Kung JT, Hsieh SL, McDevitt H, and Sytwu HK. Immunopathogenic role of TH1 cells in autoimmune diabetes: evidence from a T1 and T2 doubly transgenic non-obese diabetic mouse model. J Autoimmun 25: 181-192, 2005.
50. Hunter P. Xeno's paradox: why pig cells are better for tissue transplants than human cells. EMBO Rep 10: 554-557, 2009.
51. Jaramillo MC, Frye JB, Crapo JD, Briehl MM, and Tome ME. Increased manganese superoxide dismutase expression or treatment with manganese porphyrin potentiates dexamethasone-induced apoptosis in lymphoma cells. Cancer Res 69: 5450-5457, 2009.
52. Jaswal S, Mehta HC, Sood AK, and Kaur J. Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin Chim Acta 338: 123-129, 2003.
53. Jiang Z and Woda BA. Cytokine gene expression in the islets of the diabetic Biobreeding/Worcester rat. J Immunol 146: 2990-2994, 1991.
54. Jin X, Cong C, Yuan Y, Mai G, Wei LL, Chen YN, Cheng JQ, and Lu YR. [Toxic effect of immunosuppression agent Everolimus on insuloma cells and pancreatic islets of SD rat]. Sichuan Da Xue Xue Bao Yi Xue Ban 41: 68-72, 2010.
55. Jungsuwadee P, Weaver MR, Gally F, and Oberley-Deegan RE. The metalloporphyrin antioxidant, MnTE-2-PyP, inhibits Th2 cell immune responses in an asthma model. Int J Mol Sci 13: 9785-9797, 2012.
56. Kagi D, Odermatt B, Seiler P, Zinkernagel RM, Mak TW, and Hengartner H. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 186: 989-997, 1997.
57. Karin M, Liu Z, and Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246, 1997.
58. Kazak L, Reyes A, and Holt IJ. Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol 13: 659-671, 2012.
59. Khan I, Batinic-Haberle I, and Benov LT. Effect of potent redox-modulating manganese porphyrin, MnTM-2-PyP, on the Na(+)/H(+) exchangers NHE-1 and NHE-3 in the diabetic rat. Redox Rep 14: 236-242, 2009.
60. Krause KH and Bedard K. NOX enzymes in immuno-inflammatory pathologies. Semin Immunopathol 30: 193-194, 2008.
61. Kubin M, Kamoun M, and Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 180: 211-222, 1994.
62. Kurrer MO, Pakala SV, Hanson HL, and Katz JD. Beta cell apoptosis in T cell-mediated autoimmune diabetes. Proc Natl Acad Sci U S A 94: 213-218, 1997.
63. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4: 181-189, 2004.
64. Lawless C, Jurk D, Gillespie CS, Shanley D, Saretzki G, von Zglinicki T, and Passos JF. A stochastic step model of replicative senescence explains ROS production rate in ageing cell populations. PLoS One 7: e32117, 2012.
65. Lehuen A, Diana J, Zaccone P, and Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 10: 501-513, 2010.
66. Lenzen S. Oxidative stress: the vulnerable beta-cell. Biochem Soc Trans 36: 343-347, 2008.
67. Li N, Wang Y, Forbes K, Vignali KM, Heale BS, Saftig P, Hartmann D, Black RA, Rossi JJ, Blobel CP, Dempsey PJ, Workman CJ, and Vignali DA. Metalloproteases regulate Tcell proliferation and effector function via LAG-3. EMBO J 26: 494-504, 2007.
68. Limon-Pacheco J and Gonsebatt ME. The role of antioxidants and antioxidant-related enzymes in protective responses to environmentally induced oxidative stress. Mutat Res 674: 137-147, 2009.
69. Lin MS, Tse HM, Delmastro MM, Bertera S, Wong CT, Lakomy R, He J, Sklavos MM, Coudriet GM, Pietropaolo M, Trucco MM, and Piganelli JD. A multivalent vaccine for type 1 diabetes skews T cell subsets to Th2 phenotype in NOD mice. Immunol Res 50: 213-220, 2011.
70. Liu B, Chen Y, and St Clair DK. ROS and p53: a versatile partnership. Free Radic Biol Med 44: 1529-1535, 2008.
71. Liu H, Colavitti R, Rovira II, and Finkel T. Redox-dependent transcriptional regulation. Circ Res 97: 967-974, 2005.
72. Liu W, Ma MJ, Tang F, He C, Zhang XA, Jiang LF, Xin DS, Hu CY, Looman C, and Cao WC. Host immune response to A(H1N1)pdm09 vaccination and infection: a one-year prospective study on six cohorts of subjects. Vaccine 30: 4785-4789, 2012.
73. Luft T, Jefford M, Luetjens P, Hochrein H, Masterman KA, Maliszewski C, Shortman K, Cebon J, and Maraskovsky E. IL-1 beta enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cellindependent DC activation. J Immunol 168: 713-722, 2002.
74. Lynch RM, Tran L, Louder MK, Schmidt SD, Cohen M, Dersimonian R, Euler Z, Gray ES, Abdool Karim S, Kirchherr J, Montefiori DC, Sibeko S, Soderberg K, Tomaras G, Yang ZY, Nabel GJ, Schuitemaker H, Morris L, Haynes BF, and Mascola JR. The development of CD4 binding site antibodies during HIV-1 infection. J Virol 86: 7588-7595, 2012.
75. Makinde AY, Luo-Owen X, Rizvi A, Crapo JD, Pearlstein RD, Slater JM, and Gridley DS. Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation. Anticancer Res 29: 107-118, 2009.
76. Makinde AY, Rizvi A, Crapo JD, Pearlstein RD, Slater JM, and Gridley DS. A metalloporphyrin antioxidant alters cytokine responses after irradiation in a prostate tumor model. Radiat Res 173: 441-452, 2010.
77. Mandrup-Poulsen T, Bendtzen K, Dinarello CA, and Nerup J. Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. J Immunol 139: 4077-4082, 1987.
78. Mandrup-Poulsen T, Egeberg J, Nerup J, Bendtzen K, Nielsen JH, and Dinarello CA. Ultrastructural studies of time-course and cellular specificity of interleukin-1 mediated islet cytotoxicity. Acta Pathol Microbiol Immunol Scand C 95: 55-63, 1987.
79. Marchioli R, Schweiger C, Levantesi G, Tavazzi L, and Valagussa F. Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. Lipids 36 Suppl: S53-S63, 2001.
80. Martins GA, Hutchins AS, and Reiner SL. Transcriptional activators of helper T cell fate are required for establishment but not maintenance of signature cytokine expression. J Immunol 175: 5981-5985, 2005.
81. Meyer M, Pahl HL, and Baeuerle PA. Regulation of the transcription factors NF-kappa B and AP-1 by redox changes. Chem Biol Interact 91: 91-100, 1994.
82. Minakami R and Sumimotoa H. Phagocytosis-coupled activation of the superoxide-producing phagocyte oxidase, a member of the NADPH oxidase (nox) family. Int J Hematol 84: 193-198, 2006.
83. Moeller BJ, Batinic-Haberle I, Spasojevic I, Rabbani ZN, Anscher MS, Vujaskovic Z, and Dewhirst MW. Amanganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness. Int J Radiat Oncol Biol Phys 63: 545-552, 2005.
84. Mukhopadhyay P, Horvath B, Zsengeller Z, Batkai S, Cao Z, Kechrid M, Holovac E, Erdelyi K, Tanchian G, Liaudet L, Stillman IE, Joseph J, Kalyanaraman B, and Pacher P. Mitochondrial reactive oxygen species generation triggers inflammatory response and tissue injury associated with hepatic ischemia-reperfusion: therapeutic potential ofmitochondrially targeted antioxidants. Free Radic Biol Med 53: 1123-1138, 2012.
85. Muller JM, Rupec RA, and Baeuerle PA. Study of gene regulation by NF-kappa B and AP-1 in response to reactive oxygen intermediates. Methods 11: 301-312, 1997.
86. Murthy A, Shao YW, Narala SR, Molyneux SD, Zuniga-Pflucker JC, and Khokha R. Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis. Immunity 36: 105-119, 2012.
87. Nauseef WM. Nox enzymes in immune cells. Semin Immunopathol 30: 195-208, 2008.
88. Nelson KK and Melendez JA. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 37: 768-784, 2004.
89. Noguchi H, Matsumoto S, Matsushita M, Kobayashi N, Tanaka K, Matsui H, and Tanaka N. Immunosuppression for islet transplantation. Acta Med Okayama 60: 71-76, 2006.
90. O'Garra A, Vieira PL, Vieira P, and Goldfeld AE. IL-10- producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest 114: 1372-1378, 2004.
91. O'Reilly LA, Hutchings PR, Crocker PR, Simpson E, Lund T, Kioussis D, Takei F, Baird J, and Cooke A. Characterization of pancreatic islet cell infiltrates in NO Dmice: effect of cell transfer and transgene expression. Eur J Immunol 21: 1171-1180, 1991.
92. Ogier-Denis E, Mkaddem SB, and Vandewalle A. NOX enzymes and toll-like receptor signaling. Semin Immunopathol 30: 291-300, 2008.
93. Olcott AP, Tocco G, Tian J, Zekzer D, Fukuto J, Ignarro L, and Kaufman DL. A salen-manganese catalytic free radical scavenger inhibits type 1 diabetes and islet allograft rejection. Diabetes 53: 2574-2580, 2004.
94. Ortis F, Miani M, Colli ML, Cunha DA, Gurzov EN, Allagnat F, Chariot A, and Eizirik DL. Differential usage of NF-kappaB activating signals by IL-1beta and TNF-alpha in pancreatic beta cells. FEBS Lett 586: 984-989, 2012.
95. Pacher P, Nivorozhkin A, and Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58: 87-114, 2006.
96. Park KS, Kim JH, Kim MS, Kim JM, Kim SK, Choi JY, Chung MH, Han B, Kim SY, and Lee HK. Effects of insulin and antioxidant on plasma 8-hydroxyguanine and tissue 8- hydroxydeoxyguanosine in streptozotocin-induced diabetic rats. Diabetes 50: 2837-2841, 2001.
97. Pearlstein RD, Higuchi Y, Moldovan M, Johnson K, Fukuda S, Gridley DS, Crapo JD, Warner DS, and Slater JM. Metalloporphyrin antioxidants ameliorate normal tissue radiation damage in rat brain. Int J Radiat Biol 86: 145-163, 2010.
98. Pietropaolo M, Surhigh JM, Nelson PW, and Eisenbarth GS. Primer: immunity and autoimmunity. Diabetes 57: 2872-2882, 2008.
99. Piganelli JD, Flores SC, Cruz C, Koepp J, Batinic-Haberle I, Crapo J, Day B, Kachadourian R, Young R, Bradley B, and Haskins K. A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 51: 347-355, 2002.
100. Rabbani ZN, Spasojevic I, Zhang X, Moeller BJ, Haberle S, Vasquez-Vivar J, Dewhirst MW, Vujaskovic Z, and Batinic-Haberle I. Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2- PyP(5+), via suppression of oxidative stress in a mousemodel of breast tumor. Free Radic Biol Med 47: 992-1004, 2009.
101. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes 43: 613-621, 1994.
102. 2, a necessary evil for cell signaling. Science 312: 1882-1883, 2006.
103. Rodriguez-Vargas JM, Ruiz-Magana MJ, Ruiz-Ruiz C, Majuelos-Melguizo J, Peralta-Leal A, Rodriguez MI, Munoz-Gamez JA, de Almodovar MR, Siles E, Rivas AL, Jaattela M, and Oliver FJ. ROS-induced DNA damage and PARP-1 are required for optimal induction of starvationinduced autophagy. Cell Res 22: 1181-1198, 2012.
104. Rosmalen JG, Martin T, Dobbs C, Voerman JS, Drexhage HA, Haskins K, and Leenen PJ. Subsets of macrophages and dendritic cells in nonobese diabetic mouse pancreatic inflammatory infiltrates: correlation with the development of diabetes. Lab Invest 80: 23-30, 2000.
105. Saba H, Batinic-Haberle I, Munusamy S, Mitchell T, Lichti C, Megyesi J, and MacMillan-Crow LA. Manganese porphyrin reduces renal injury and mitochondrial damage during ischemia/reperfusion. Free Radic Biol Med 42: 1571-1578, 2007.
106. Sahin E and DePinho RA. Axis of ageing: telomeres, p53 and mitochondria. Nat Rev Mol Cell Biol 13: 397-404, 2012.
107. Sakuma Y, Ricordi C, Miki A, Yamamoto T, Pileggi A, Khan A, Alejandro R, Inverardi L, and Ichii H. Factors that affect human islet isolation. Transplant Proc 40: 343-345, 2008.
108. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, and Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440, 2000.
109. Saxena A, Desbois S, Carrie N, Lawand M, Mars LT, and Liblau RS. Tc17 CD8+ T cells potentiate Th1-mediated autoimmune diabetes in a mouse model. J Immunol 189: 3140-3149, 2012.
110. Seleme MC, Lei W, Burg AR, Goh KY, Metz A, Steele C, and Tse HM. Dysregulated TLR3-dependent signaling and innate immune activation in superoxide-deficient macrophages from nonobese diabetic mice. Free Radic Biol Med 52: 2047-2056, 2012.
111. Sheng H, Spasojevic I, Tse HM, Jung JY, Hong J, Zhang Z, Piganelli JD, Batinic-Haberle I, and Warner DS. Neuroprotective efficacy from a lipophilic redox-modulating Mn(III) N-Hexylpyridylporphyrin, MnTnHex-2-PyP: rodent models of ischemic stroke and subarachnoid hemorrhage. J Pharmacol Exp Ther 338: 906-916, 2011.
112. Shinomiya M, Nadano S, Shinomiya H, and Onji M. In situ characterization of dendritic cells occurring in the islets of nonobese diabetic mice during the development of insulitis. Pancreas 20: 290-296, 2000.
113. Silveira PA, Johnson E, Chapman HD, Bui T, Tisch RM, and Serreze DV. The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors. Eur J Immunol 32: 3657-3666, 2002.
114. Sivitz WI and Yorek MA. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal 12: 537-577, 2010.
115. Sklavos MM, Bertera S, Tse HM, Bottino R, He J, Beilke JN, Coulombe MG, Gill RG, Crapo JD, Trucco M, and Piganelli JD. Redox modulation protects islets from transplant-related injury. Diabetes 59: 1731-1738, 2010.
116. Sklavos MM, Tse HM, and Piganelli JD. Redox modulation inhibits CD8 T cell effector function. Free Radic Biol Med 45: 1477-1486, 2008.
117. Spasojevic I, Chen Y, Noel TJ, Fan P, Zhang L, Reboucas JS, St Clair DK, and Batinic-Haberle I. Pharmacokinetics of the potent redox-modulating manganese porphyrin, MnTE-2- PyP(5+), in plasma and major organs of B6C3F1 mice. Free Radic Biol Med 45: 943-949, 2008.
118. Stosic-Grujicic SD, Miljkovic DM, Cvetkovic ID, Maksimovic-Ivanic DD, and Trajkovic V. Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes. J Autoimmun 22: 267-276, 2004.
119. Stucker F, Marti HP, and Hunger RE. Immunosuppressive drugs in organ transplant recipients-rationale for critical selection. Curr Probl Dermatol 43: 36-48, 2012.
120. Sullivan AN, Bryant EA, and Mark LA. Malignant melanoma in transplant patients: a case report and review of the literature. Cutis 89: 133-136, 2012.
121. Suri A and Katz JD. Dissecting the role of CD4+ T cells in autoimmune diabetes through the use of TCR transgenic mice. Immunol Rev 169: 55-65, 1999.
122. Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman AL, and Groves JT. Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 8: 571-580, 2002.
123. Taplin CE and Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity 41: 11-18, 2008.
124. Taylor AL, Watson CJ, and Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit RevOncol Hematol 56: 23-46, 2005.
125. Thomas D, Zaccone P, and Cooke A. The role of regulatory T cell defects in type I diabetes and the potential of these cells for therapy. Rev Diabet Stud 2: 9-18, 2005.
126. Thomas HE and Kay TW. Beta cell destruction in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse. Diabetes Metab Res Rev 16: 251-261, 2000.
127. Thomas R. Signal 3 and its role in autoimmunity. Arthritis Res Ther 6: 26-27, 2004.
128. Tovmasyan A, Sheng H, Weitner T, Arulpragasam A, Lu M, Warner DS, Vujaskovic Z, Spasojevic I, and Batinic-Haberle I. Design, mechanism of action, bioavailability and therapeutic effects of Mn porphyrin-based redox modulators. Med Princ Pract 22: 103-130, 2012.
129. Toyokuni S, Okamoto K, Yodoi J, and Hiai H. Persistent oxidative stress in cancer. FEBS Lett 358: 1-3, 1995.
130. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146, 2003.
131. Tse HM, Milton MJ, and Piganelli JD. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic Biol Med 36: 233-247, 2004.
132. Tse HM, Milton MJ, Schreiner S, Profozich JL, Trucco M, and Piganelli JD. Disruption of innate-mediated proinflammatory cytokine and reactive oxygen species third signal leads to antigen-specific hyporesponsiveness. J Immunol 178: 908-917, 2007.
133. Vignali DA, Collison LW, and Workman CJ. How regulatory T cells work. Nat Rev Immunol 8: 523-532, 2008.
134. Wachlin G, Augstein P, Schroder D, Kuttler B, Kloting I, Heinke P, and Schmidt S. IL-1beta, IFN-gamma and TNFalpha increase vulnerability of pancreatic beta cells to autoimmune destruction. J Autoimmun 20: 303-312, 2003.
135. Wang Y, Pontesilli O, Gill RG, La Rosa FG, and Lafferty KJ. The role of CD4+ and CD8+ T cells in the destruction of islet grafts by spontaneously diabetic mice. Proc Natl Acad Sci U S A 88: 527-531, 1991.
136. Wong FS, Siew LK, Scott G, Thomas IJ, Chapman S, Viret C, and Wen L. Activation of insulin-reactive CD8 T-cells for development of autoimmune diabetes. Diabetes 58: 1156-1164, 2009.
137. Wood KJ and Goto R. Mechanisms of rejection: current perspectives. Transplantation 93: 1-10, 2012.
138. Workman CJ and Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol 33: 970-979, 2003.
139. Workman CJ and Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 174: 688-695, 2005.
140. Wu TJ, Khoo NH, Zhou F, Day BJ, and Parks DA. Decreased hepatic ischemia-reperfusion injury by manganeseporphyrin complexes. Free Radic Res 41: 127-134, 2007.
141. Yang Z, Chen M, Ellett JD, Fialkow LB, Carter JD, McDuffie M, and Nadler JL. Autoimmune diabetes is blocked in Stat4-deficient mice. J Autoimmun 22: 191-200, 2004.
142. Ye X, Fels D, Tovmasyan A, Aird KM, Dedeugd C, Allensworth JL, Kos I, Park W, Spasojevic I, Devi GR, Dewhirst MW, Leong KW, and Batinic-Haberle I. Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate. Free Radic Res 45: 1289-1306, 2011.
143. Yoneda R, Yokono K, Nagata M, Tominaga Y, Moriyama H, Tsukamoto K, Miki M, Okamoto N, Yasuda H, Amano K, and Kasuga M. CD8 cytotoxic T-cell clone rapidly transfers autoimmune diabetes in very young NOD and MHC class I-compatible scid mice. Diabetologia 40: 1044-1052, 1997.
144. Zervou MI, Mamoulakis D, Panierakis C, Boumpas DT, and Goulielmos GN. STAT4: a risk factor for type 1 diabetes? Hum Immunol 69: 647-650, 2008.
145. Zhang N, Su D, Qu S, Tse T, Bottino R, Balamurugan AN, Xu J, Bromberg JS, and Dong HH. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 55: 2429-2436, 2006.
146. Zhao Y, Chaiswing L, Oberley TD, Batinic-Haberle I, St Clair W, Epstein CJ, and St Clair D. A mechanism-based antioxidant approach for the reduction of skin carcinogenesis. Cancer Res 65: 1401-1405, 2005.